Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | FER | P16591 | 1/20 | 0.48 |
| ▸ | LTK | P29376 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6358112 | 1.00 | MAPT (0.50) | MAPTGAALRRK2ACVR1MAOA | |
| SCHEMBL6350561 | 0.84 | ACVR1 (0.40) | MAPTGAALRRK2ACVR1MAOA | |
| SCHEMBL6350563 | 0.84 | ACVR1 (0.40) | MAPTGAALRRK2ACVR1MAOA | |
| SCHEMBL6351020 | 0.84 | NTRK1 (0.46) | MAPTGAALRRK2ACVR1MAOA | |
| SCHEMBL6351016 | 0.84 | NTRK1 (0.46) | MAPTGAALRRK2ACVR1MAOA | |
| SCHEMBL6353623 | 0.82 | MAOA (0.40) | MAPTLRRK2ACVR1MAOAMAOB | |
| SCHEMBL6353626 | 0.82 | MAOA (0.40) | MAPTLRRK2ACVR1MAOAMAOB | |
| SCHEMBL341087 | 0.82 | MAPT (0.54) | MAPTGAALRRK2ACVR1MAOA | |
| SCHEMBL6351562 | 0.80 | TLK2 (0.44) | MAPTGAACDK2KDM4ELMNA | |
| SCHEMBL6352879 | 0.80 | CHEK1 (0.47) | MAPTGAALRRK2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | claimed |
| EP-1396490-A1 | 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | claimed |
| JP-2005298437-A | 3-QUINOLIN-2(1H)-YLIDENE INDOLIN-2-ONE DERIVATIVE | ASTELLAS PHARMA INC | 2005-10-27 | — | — | JP | disclosed |
| JP-2005145928-A | PHARMACEUTICAL COMPOSITION CONTAINING 3-QUINOLIN-2(1H)-YLIDENE INDOLIN-2-ONE DERIVATIVE AS ACTIVE COMPONENT | YAMANOUCHI PHARMACEUT CO LTD | 2005-06-09 | — | — | JP | disclosed |
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| CN-1511151-A | 3-quinoline-2-(1H)-ylideneindolin-2-one derivatives | ֮����ҩ��ʽ���� | 2004-07-07 | — | — | CN | disclosed |
| CN-1511151-A | 3-quinoline-2-(1H)-ylideneindolin-2-one derivatives | ֮����ҩ��ʽ���� | 2004-07-07 | — | — | CN | disclosed |
| EP-1396490-A1 | 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
| EP-1396490-A1 | 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094809-A1 | 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
| EP-0794184-B1 | 6-METHOXY-1H-BENZOTRIAZOLE-5-CARBOXAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-05-30 | — | — | EP | disclosed |
| US-5932568-A | GASTROINTESTINAL DISORDERS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1999-08-03 | — | — | US | disclosed |
| US-5686482-A | DOPAMINE RECEPTOR ANTAGONIST | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-11 | — | — | US | disclosed |
| EP-0794184-A1 | 6-METHOXY-1H-BENZOTRIAZOLE-5-CARBOXAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1997-09-10 | — | — | EP | disclosed |
| EP-0757985-A1 | N-(3-PYRROLIDINYL)BENZAMIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0251417-B1 | 4-(AROYLAMINO) PIPERIDINEBUTANAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-04-14 | — | — | EP | disclosed |
| US-4990521-A | Treating diarhea | JANSSEN PHARMACEUTICA (BE) | 1991-02-05 | — | — | US | disclosed |
| EP-0251417-A2 | 4-(aroylamino) piperidinebutanamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | KDR, FLT4, FLT1 | MAPT 3729/4885GAA 1160/4885LRRK2 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.